drugset / Trial / NCT01011335

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. The purpose of this study is to find the right dose of a new vaccine that is safe and produces a good immune response (how well your body recognizes and defends itself against harmful foreign substances). There are two Staphylococcus aureus toxoids (components or antigens) under investigation in this study; one of them is a protein known as rAT and the other is a protein known as rLukS-PV. They are being developed to see if they are effective at preventing infections caused by the bacteria Staphylococcus aureus.

Timeline

Start
2009-11
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalent rLukS-PV / rAT Unknown 10 ug —
Subject Bivalent rLukS-PV / rAT Unknown 25 ug —
Subject Bivalent rLukS-PV / rAT Unknown 50 ug —
Subject rAT Unknown 10 ug —
Subject rAT Unknown 25 ug —
Subject rAT Unknown 50 ug —
Subject rAT Unknown 100 ug —
Subject rLukS-PV Unknown 10 ug —
Subject rLukS-PV Unknown 25 ug —
Subject rLukS-PV Unknown 50 ug —
Subject rLukS-PV Unknown 100 ug —